Skip to main content

Advertisement

SpringerLink
Log in

The Baroreflex in Hypertension

  • Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension is a complex syndrome that increases the risk of developing other medical comorbidities and interacts with other medical conditions to increase the risk of target end-organ damage such as cardiovascular disease, stroke, and renal disease. Hypertension remains under-recognized and poorly controlled in the USA and worldwide. In some patients, hypertension is resistant to optimal medical therapy. Over the last few decades, there has been an increasing understanding of the role of the sympathetic nervous system in the development and maintenance of hypertension. This update reviews the physiology and role of the sympathetic nervous system in hypertension and pharmacological and interventional treatments directed at nervous system involvement in secondary hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;364:217–23.

    Article  Google Scholar 

  2. Carey RM. Resistant hypertension. Hypertension. 2013;61:746. This article provides a clear definition of what true resistant hypertension involves. It describes its prevalence and the various potential treatments including medications and interventional treatments. It also describes some of the pitfalls such as inadequate dosing regimens, inappropriate pharmacological combinations, and lack of treatment intensification or medication adherence as reasons for why hypertension is difficult to control.

    Article  CAS  PubMed  Google Scholar 

  3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2009;51:1403–19.

    Article  Google Scholar 

  4. Fisher JP, Young CN, Fadel PJ. Central sympathetic overactivity: maladies and mechanisms. Autonm Neurosci. 2009;148:5–15.

    Article  Google Scholar 

  5. Lovic D, Manolis AJ, et al. The pathophysiological basis of carotid baroreceptor stimulation for the treatment of resistant hypertension. Curr Vasc Pharmacol. 2014;12:16–22. This article describes physiology of blood pressure regulation, specifically role carotid baroreceptors. It provides a summary of animal and human studies on long-term effect of baroreceptors on hypertension.

    Article  CAS  PubMed  Google Scholar 

  6. Drummond HA, Price MP, Welsh MJ, et al. A molecular component of the arterial baroreceptor mechanotransducer. Neuron. 1998;21:1435–41.

    Article  CAS  PubMed  Google Scholar 

  7. Lovic D, Manolis AJ, et al. The pathophysiological basis of carotid baroreceptor stimulation for the treatment of resistant hypertension. Curr Vasc Pharmacol. 2014;12:16–22.

    Article  CAS  PubMed  Google Scholar 

  8. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev. 1994;74:323–264.

    CAS  PubMed  Google Scholar 

  9. McCubbin JW, Green JH, Page IH. Baroreceptor function in chronic renal hypertension. Circulation Res. 1956;4:205–10.

    Article  CAS  PubMed  Google Scholar 

  10. Matton G. Carotid sinus and neurogenic and renal hypertension. J Physiol. 1954;126:13P–4P.

    Google Scholar 

  11. Bishop VS, Haywood JR, Shade RE, et al. Aortic baroreceptor deafferentation in the baboon. J Appl Physiol. 1986;60:798–801.

    CAS  PubMed  Google Scholar 

  12. Schwartz SI, Grittith LS, Neistadt A, et al. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg. 1967;114:5–15.

    Article  CAS  PubMed  Google Scholar 

  13. Izzo JL, Sica DA and Black HR; (2008) ‘Renal sympathetic nerves and extracellular fluid volume regulation’. In: Hypertension primer. Philadelphia: Lippincott Williams and Wilkins.

  14. Cowley Jr AW, Liard JF, Guyton AC. Role of the baroreceptor reflex in daily control of arterial blood pressure and other variables in dogs. Circ Res. 1973;32:564–76.

    Article  PubMed  Google Scholar 

  15. Charkoudian N, Rabbitts JA. Sympathetic neural mechanisms in human cardiovascular health and disease. Mayo Clin Proc. 2009;84:822–30.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.

    Article  CAS  PubMed  Google Scholar 

  17. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–80.

    Article  CAS  PubMed  Google Scholar 

  18. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982–12.

    Article  CAS  PubMed  Google Scholar 

  19. Pimenta E, Gaddam KK, Oparis S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Furberg CD, Wright JT, Davis BR, et al. ALLHAT. JAMA. 2002;288(23):2981–97.

    Article  CAS  Google Scholar 

  21. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

    Article  CAS  PubMed  Google Scholar 

  22. James PA, Opari S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311(5):507–20. This publication provides JNC8’s latest evidence-based recommendations for the management of hypertension. It makes nine recommendations that are based solely on randomized control trial data rather than on observational studies such as in JNC7 guidelines. Its main shift is that in those aged 60 and above, one should initiate pharmacologic treatment to lower systolic blood pressure of 150 mmHg or higher or diastolic BP of 90 mmHg or higher.

    Article  CAS  PubMed  Google Scholar 

  23. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921–6.

    Article  CAS  PubMed  Google Scholar 

  24. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.

    Article  CAS  PubMed  Google Scholar 

  25. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–30.

    Article  CAS  PubMed  Google Scholar 

  26. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15:333–9.

    Article  CAS  PubMed  Google Scholar 

  27. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1392–401. This prospective, single-blind, randomized, sham-controlled study showed that there was a significant drop in ambulatory and office-based blood pressure with both patients with renal denervation and those with the sham procedure. However, there was no significant difference in systolic blood pressure reduction between the two groups after 6 months.

    Article  Google Scholar 

  28. Nicholas AP, Hokfelt T, Pieribone VA. The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci. 1996;17:245–55.

    Article  CAS  PubMed  Google Scholar 

  29. Edwards LP, Brown-Bryan TA, Mclean L, et al. Pharmacological properties of the central antihypertensive agent. Moxonidine Cardiovasc Ther. 2012;30:199–208.

    Article  CAS  Google Scholar 

  30. Furberg CD, Wright JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.

    Article  CAS  Google Scholar 

  31. James PA, Opari S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311(5):507–20.

    Article  CAS  PubMed  Google Scholar 

  32. Dahlof B, Devereux RB, Kjeldsen SE, LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995–1003.

    Article  CAS  PubMed  Google Scholar 

  33. Hamilton WF, Richards DW. Ouput of the heart. In: Fishman AP, Richards DW, editors. Circulation of the blood. Men and ideas. Bethesda: American Physiological Society; 1982. p. 87–90.

    Google Scholar 

  34. Adson AW, McCraig W, Brown GE. Surgery in its relation to hypertension. Surg Gynecol Obstet. 1936;62:314–31.

    Google Scholar 

  35. Smithwick RH, Bush RD, Kinsey D, Whitelaw GP. Hypertension and associated cardiovascular disease: comparison of male and female mortality rates and their influence on selection of therapy. J Am Med Assoc. 1956;160:1023–6.

    Article  CAS  PubMed  Google Scholar 

  36. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44:1213–8.

    Article  PubMed  Google Scholar 

  37. Schmidli J, Savolainen H, Eckstein F, et al. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular. 2007;15:63–9.

    Article  PubMed  Google Scholar 

  38. Scheffers IJM, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254–8.

    Article  PubMed  Google Scholar 

  39. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:765–73. This was the first large-scale randomized, double-blind, placebo-controlled device clinical trial that assessed the efficacy and safety of the Rheos baroreflex activation therapy (BAT) in patients with resistant hypertension via five prespecified coprimary endpoints. Though it did not meet short-term safety and short-term efficacy endpoints, it showed mean reductions in SBP of up to 35 mmHg at 12 months with over 50 % of patients achieving a SBP of <140 mmHg.

    Article  PubMed  Google Scholar 

  40. Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270–6. This is a single-arm, open-label European study enrolled 30 patients with resistant hypertension to carotid baroreflex activation therapy. BAT caused a blood pressure reduction of 22.3 ± 9.8 mmHg. Its safety profile was comparable to pacemaker implantation.

    Article  PubMed  Google Scholar 

  41. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245–53.

    Article  CAS  PubMed  Google Scholar 

  42. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1266 patients. JAMA. 1953;152:1501–4.

    Article  CAS  Google Scholar 

  43. Hinton JW, Lord JW. The surgical treatment of essential hypertension; a comparison of the results of the classical Smithwick operation and the extensive thoracolumbar sympathectomy. Surg Clin North Am. 1948;28(2):290–3.

    CAS  PubMed  Google Scholar 

  44. Grimson KS, Orgain ES, Anderson B, et al. Total thoracic and partial to lower lumbar sympathectomy and celiac ganglionectomy for hypertension. Ann Surg. 1953;152:1501–4.

    Google Scholar 

  45. Schlaich MP, Sobodka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932–4.

    Article  CAS  PubMed  Google Scholar 

  46. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.

    Article  PubMed  Google Scholar 

  47. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobodka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903–9.

    Article  Google Scholar 

  48. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012;30:874–6. This article questions whether we should focus on ambulatory blood pressure reduction rather than office blood pressure reduction. It reviews the big discrepancy between impressive office blood pressure reductions with conventional antihypertensive treatment or invasive methods with the more believable ambulatory blood pressure reduction. It raises the validity of office readings.

    Article  CAS  PubMed  Google Scholar 

  49. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1392–401.

    Article  Google Scholar 

  50. Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526–32. This study emphasized the importance of drug adherence. Out of 18 patients referred to hypertension specialists for treatment of resistant hypertension by renal denervation, 12 were eliminated from the study including five who had normalization of blood pressure by being monitored while taking their blood pressure medications. It demonstrates that medication noncompliance is common and speculates whether renal denervation truly works or whether it helps by improving drug adherence.

    Article  CAS  PubMed  Google Scholar 

  51. Fadl Elmula FE, Hoffman P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63:1–9. This small study with 19 patients looked at the blood pressure-lowering effect of renal sympathetic denervation versus clinically adjusted drug treatment in patients with confirmed resistant hypertension. It ruled out patients with medication noncompliance. At 6 months, systolic and diastolic blood pressure was lowered in the drug-adjusted group as compared to the renal denervation group.

    Article  Google Scholar 

  52. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–85.

    Article  CAS  PubMed  Google Scholar 

  53. Chapleau MW. Arterial baroreflexes. Hypertension primer: the essential hypertension of high blood pressure, 4th edn. London: Lippincott Williams & Wilkins; 2008.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

John P. Gassler reports personal fees from Merck. Genaro Fernandez, Junsoo Alex Lee, and Lynn C. Liu declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. University of Rochester Cardiology Division, Strong Memorial Hospital, University of Rochester Medical Center, 601 Elmwood Ave, Box 679-C, Rochester, NY, 14642, USA

    Genaro Fernandez & Junsoo Alex Lee

  2. University of Rochester Neurology Department, Strong Memorial Hospital, University of Rochester Medical Center, 601 Elmwood Ave, Box 679-C, Rochester, NY, 14642, USA

    Lynn C. Liu

  3. University of Rochester Cardiology Outpatient Anticoagulation Management Service, Strong Memorial Hospital, University of Rochester Medical Center, 601 Elmwood Ave, Box 679-C, Rochester, NY, 14642, USA

    John P. Gassler

Authors
  1. Genaro Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junsoo Alex Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynn C. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John P. Gassler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John P. Gassler.

Additional information

This article is part of the Topical Collection on Secondary Hypertension: Nervous System Mechanisms

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fernandez, G., Lee, J.A., Liu, L.C. et al. The Baroreflex in Hypertension. Curr Hypertens Rep 17, 19 (2015). https://doi.org/10.1007/s11906-014-0531-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-014-0531-z

Keywords

Search

Navigation